英国特发性肺纤维化人群中由生理性别决定的疾病特征和结果的差异:来自英国胸科学会间质性肺疾病登记数据的分析

IF 3.4 3区 医学 Q1 RESPIRATORY SYSTEM
Sarah Mulholland, Giles Dixon, Matthew Wells, Sam Harding, Paul White, Anne-Marie Russell, Shaney L Barratt
{"title":"英国特发性肺纤维化人群中由生理性别决定的疾病特征和结果的差异:来自英国胸科学会间质性肺疾病登记数据的分析","authors":"Sarah Mulholland, Giles Dixon, Matthew Wells, Sam Harding, Paul White, Anne-Marie Russell, Shaney L Barratt","doi":"10.1136/bmjresp-2025-003301","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Growing evidence suggests that biological sex influences the incidence, presentation, diagnosis and outcomes of many lung diseases. Understanding these differences is the first step towards precision medicine to improve patient care.</p><p><strong>Methods: </strong>In this cross-sectional study, idiopathic pulmonary fibrosis (IPF) patients enrolled in a national (UK), multicentre registry were categorised by sex and analysed for differences in demographics, pulmonary function tests, high resolution CT radiological pattern, eligibility/uptake of antifibrotics and survival.</p><p><strong>Results: </strong>Of 7177 cases, 77.8% (n=5587) were male, median age 75 years (IQR 69.5-80.5) for both sexes (p=0.83). Males were more likely to have a history of smoking (males 72.9% vs females 60.5%, p<0.001) and lower baseline median forced vital capacity (FVC) % predicted (males 76.4%, IQR 66.2-86.7 vs females 78.8%, IQR 68.6-89.1, p<0.001). Diabetes (males 22.8% vs females 15.1%) and cardiovascular disease (males 58.9% vs females 47.8%) were statistically more common in males (p<0.001), while gastro-oesophageal reflux disease (males 20% vs females 24.6%) and major depressive illness (males 0.8% vs females 2.5%) were more common in females (p<0.001). Significantly, more females experienced symptoms for >24 months prior to first clinic appointment (females 40.1% vs males 36.6%, p=0.03). While more males in the cohort met eligibility criteria for antifibrotics at baseline (pirfenidone FVC 50%-80% males 54.7% vs females 47.6%, nintedanib FVC 50%-80% males 47.0% vs females 41.5%, p<0.001), a larger proportion chose not to commence antifibrotic treatment (males 47.0% vs females 29.6%, p<0.001). Female sex was associated with longer survival; for females, the 75% Kaplan-Meier survival quartile is 7.6 years (95% CI 5.51 to 9.68 years) versus 4.3 years (95% CI 3.82 to 4.78) for males (p<0.001). Male sex (HR 1.76 (95% CI 1.22 to 2.54), p=0.002), higher age (HR 1.042 (95% CI 1.02 to 1.06), p<0.001), lower baseline FVC % predicted (HR 0.98 (95% CI 0.97 to 0.98), p<0.001) and coexistent lung cancer (HR 9.3 (95% CI 2.86 to 30.24), p<0.001) were all independently associated with worse survival.</p><p><strong>Conclusion: </strong>This is the first UK study to use national registry data to systematically evaluate IPF disease characteristics stratifying by biological sex and highlights distinct characteristics between groups. Future clinical trials should explicitly explore sex-specific targeted interventions and analyses to optimise future IPF patient care.</p>","PeriodicalId":9048,"journal":{"name":"BMJ Open Respiratory Research","volume":"12 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481391/pdf/","citationCount":"0","resultStr":"{\"title\":\"Differences in disease characteristics and outcomes as determined by biological sex in a large UK idiopathic pulmonary fibrosis population: analysis from the British Thoracic Society, Interstitial Lung Disease registry data.\",\"authors\":\"Sarah Mulholland, Giles Dixon, Matthew Wells, Sam Harding, Paul White, Anne-Marie Russell, Shaney L Barratt\",\"doi\":\"10.1136/bmjresp-2025-003301\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Growing evidence suggests that biological sex influences the incidence, presentation, diagnosis and outcomes of many lung diseases. Understanding these differences is the first step towards precision medicine to improve patient care.</p><p><strong>Methods: </strong>In this cross-sectional study, idiopathic pulmonary fibrosis (IPF) patients enrolled in a national (UK), multicentre registry were categorised by sex and analysed for differences in demographics, pulmonary function tests, high resolution CT radiological pattern, eligibility/uptake of antifibrotics and survival.</p><p><strong>Results: </strong>Of 7177 cases, 77.8% (n=5587) were male, median age 75 years (IQR 69.5-80.5) for both sexes (p=0.83). Males were more likely to have a history of smoking (males 72.9% vs females 60.5%, p<0.001) and lower baseline median forced vital capacity (FVC) % predicted (males 76.4%, IQR 66.2-86.7 vs females 78.8%, IQR 68.6-89.1, p<0.001). Diabetes (males 22.8% vs females 15.1%) and cardiovascular disease (males 58.9% vs females 47.8%) were statistically more common in males (p<0.001), while gastro-oesophageal reflux disease (males 20% vs females 24.6%) and major depressive illness (males 0.8% vs females 2.5%) were more common in females (p<0.001). Significantly, more females experienced symptoms for >24 months prior to first clinic appointment (females 40.1% vs males 36.6%, p=0.03). While more males in the cohort met eligibility criteria for antifibrotics at baseline (pirfenidone FVC 50%-80% males 54.7% vs females 47.6%, nintedanib FVC 50%-80% males 47.0% vs females 41.5%, p<0.001), a larger proportion chose not to commence antifibrotic treatment (males 47.0% vs females 29.6%, p<0.001). Female sex was associated with longer survival; for females, the 75% Kaplan-Meier survival quartile is 7.6 years (95% CI 5.51 to 9.68 years) versus 4.3 years (95% CI 3.82 to 4.78) for males (p<0.001). Male sex (HR 1.76 (95% CI 1.22 to 2.54), p=0.002), higher age (HR 1.042 (95% CI 1.02 to 1.06), p<0.001), lower baseline FVC % predicted (HR 0.98 (95% CI 0.97 to 0.98), p<0.001) and coexistent lung cancer (HR 9.3 (95% CI 2.86 to 30.24), p<0.001) were all independently associated with worse survival.</p><p><strong>Conclusion: </strong>This is the first UK study to use national registry data to systematically evaluate IPF disease characteristics stratifying by biological sex and highlights distinct characteristics between groups. Future clinical trials should explicitly explore sex-specific targeted interventions and analyses to optimise future IPF patient care.</p>\",\"PeriodicalId\":9048,\"journal\":{\"name\":\"BMJ Open Respiratory Research\",\"volume\":\"12 1\",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481391/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Open Respiratory Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjresp-2025-003301\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open Respiratory Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjresp-2025-003301","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

摘要

越来越多的证据表明,生理性别影响许多肺部疾病的发病率、表现、诊断和预后。了解这些差异是改善患者护理的精准医疗的第一步。方法:在这项横断面研究中,特发性肺纤维化(IPF)患者入组了一个国家(英国)的多中心登记中心,按性别分类,并分析了人口统计学、肺功能测试、高分辨率CT放射学模式、抗纤维化药物的资格/摄取和生存率的差异。结果:7177例病例中,77.8% (n=5587)为男性,男女中位年龄75岁(IQR 69.5-80.5) (p=0.83)。男性更有可能有吸烟史(男性72.9%对女性60.5%,首次就诊前24个月)(女性40.1%对男性36.6%,p=0.03)。虽然队列中更多的男性在基线时符合抗纤维化药物的资格标准(吡非尼酮FVC 50%-80%,男性54.7%,女性47.6%,尼达尼布FVC 50%-80%,男性47.0%,女性41.5%),结论:这是英国第一个使用国家登记数据系统地评估按生物性别分层的IPF疾病特征的研究,并突出了组间的不同特征。未来的临床试验应明确探索针对性别的针对性干预和分析,以优化未来的IPF患者护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Differences in disease characteristics and outcomes as determined by biological sex in a large UK idiopathic pulmonary fibrosis population: analysis from the British Thoracic Society, Interstitial Lung Disease registry data.

Introduction: Growing evidence suggests that biological sex influences the incidence, presentation, diagnosis and outcomes of many lung diseases. Understanding these differences is the first step towards precision medicine to improve patient care.

Methods: In this cross-sectional study, idiopathic pulmonary fibrosis (IPF) patients enrolled in a national (UK), multicentre registry were categorised by sex and analysed for differences in demographics, pulmonary function tests, high resolution CT radiological pattern, eligibility/uptake of antifibrotics and survival.

Results: Of 7177 cases, 77.8% (n=5587) were male, median age 75 years (IQR 69.5-80.5) for both sexes (p=0.83). Males were more likely to have a history of smoking (males 72.9% vs females 60.5%, p<0.001) and lower baseline median forced vital capacity (FVC) % predicted (males 76.4%, IQR 66.2-86.7 vs females 78.8%, IQR 68.6-89.1, p<0.001). Diabetes (males 22.8% vs females 15.1%) and cardiovascular disease (males 58.9% vs females 47.8%) were statistically more common in males (p<0.001), while gastro-oesophageal reflux disease (males 20% vs females 24.6%) and major depressive illness (males 0.8% vs females 2.5%) were more common in females (p<0.001). Significantly, more females experienced symptoms for >24 months prior to first clinic appointment (females 40.1% vs males 36.6%, p=0.03). While more males in the cohort met eligibility criteria for antifibrotics at baseline (pirfenidone FVC 50%-80% males 54.7% vs females 47.6%, nintedanib FVC 50%-80% males 47.0% vs females 41.5%, p<0.001), a larger proportion chose not to commence antifibrotic treatment (males 47.0% vs females 29.6%, p<0.001). Female sex was associated with longer survival; for females, the 75% Kaplan-Meier survival quartile is 7.6 years (95% CI 5.51 to 9.68 years) versus 4.3 years (95% CI 3.82 to 4.78) for males (p<0.001). Male sex (HR 1.76 (95% CI 1.22 to 2.54), p=0.002), higher age (HR 1.042 (95% CI 1.02 to 1.06), p<0.001), lower baseline FVC % predicted (HR 0.98 (95% CI 0.97 to 0.98), p<0.001) and coexistent lung cancer (HR 9.3 (95% CI 2.86 to 30.24), p<0.001) were all independently associated with worse survival.

Conclusion: This is the first UK study to use national registry data to systematically evaluate IPF disease characteristics stratifying by biological sex and highlights distinct characteristics between groups. Future clinical trials should explicitly explore sex-specific targeted interventions and analyses to optimise future IPF patient care.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BMJ Open Respiratory Research
BMJ Open Respiratory Research RESPIRATORY SYSTEM-
CiteScore
6.60
自引率
2.40%
发文量
95
审稿时长
12 weeks
期刊介绍: BMJ Open Respiratory Research is a peer-reviewed, open access journal publishing respiratory and critical care medicine. It is the sister journal to Thorax and co-owned by the British Thoracic Society and BMJ. The journal focuses on robustness of methodology and scientific rigour with less emphasis on novelty or perceived impact. BMJ Open Respiratory Research operates a rapid review process, with continuous publication online, ensuring timely, up-to-date research is available worldwide. The journal publishes review articles and all research study types: Basic science including laboratory based experiments and animal models, Pilot studies or proof of concept, Observational studies, Study protocols, Registries, Clinical trials from phase I to multicentre randomised clinical trials, Systematic reviews and meta-analyses.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信